NeoGenomics Inc. (NEO)
Summary
NeoGenomics (NEO) Soars 7.2%: Is Further Upside Left in the Stock?
NeoGenomics (NEO) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript
NeoGenomics, Inc. (NEO) Q1 2026 Earnings Call Transcript
Neo Energy Metals shares surge 33% as ex-Sibanye chief Froneman joins as chairman
Neo Energy Metals PLC (LSE:NEO) shares surged 33% to 11.02p after the uranium and gold developer announced a sweeping boardroom overhaul headlined by the appointment of Neal Froneman, the former chief executive of mining giant Sibanye-Stillwater, as independent non-executive chairman. Froneman, who led Sibanye-Stillwater from its formation in January 2013 until September 2025, oversaw its transformation from a 1.5 million-ounce South African gold producer into a globally diversified metals company and the world's largest primary producer of platinum group metals.
NeoGenomics Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| CE Curtis Ellergodt Rothschild Investment LLC | 305 | $3,222.31 | $4,398.1 | $1,175.79 | 36.49% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 2,000 | $81,280 | $28,727 | -$52,553 | -64.66% |
 Farallon Capital Farallon Capital Management LLC | 19,000 | $223,440 | $272,898.9 | $49,458.9 | 22.14% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 243,617 | $1.81M | $3.5M | $1.69M | 93.57% |
| BG Bart Gancher Intech Investment Management LLC | 28,774 | $299,690.17 | $413,194.64 | $113,504.47 | 37.87% |
NeoGenomics Inc. (NEO) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has NeoGenomics Inc. ever had a stock split?
NeoGenomics Inc. Profile
| Professional Services Industry | Industrials Sector | Anthony Zook CEO | NASDAQ (CM) Exchange | 64049M209 CUSIP |
| US Country | 2,500 Employees | 17 Dec 2020 Last Dividend | 16 Apr 2003 Last Split | 2 Nov 1999 IPO Date |
Overview
NeoGenomics, Inc. is a specialized laboratory network that focuses on cancer diagnostics and operates within the United States and the United Kingdom. Since its inception in 2001 and based in Fort Myers, Florida, the company has grown to provide a comprehensive range of testing services through its Clinical Services and Advanced Diagnostics segments. These services cater to an array of clients including hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. With a strong emphasis on supporting the diagnosis, treatment, and monitoring of cancer, NeoGenomics stands out for its dedication to advancing oncology diagnostics.
Products and Services
NeoGenomics, Inc. offers a diverse portfolio of diagnostic services, further detailed below:
- Cytogenetics Testing Services: This service examines both normal and abnormal chromosomes to understand their link to diseases. It's pivotal for revealing genetic conditions related to chromosome abnormalities.
- Fluorescence In-Situ Hybridization (FISH) Testing Services: Specializing in detecting and pinpointing the presence or absence of specific DNA sequences and genes on chromosomes, FISH plays a crucial role in genetic disease diagnosis and management.
- Flow Cytometry Testing Services: By measuring the physical and chemical characteristics of cell populations, this service provides invaluable data for research and clinical purposes, particularly in hematology.
- Immunohistochemistry and Digital Imaging Testing Services: These services focus on localizing cellular proteins in tissue sections. Moreover, they enable clients to visualize scanned slides and perform quantitative analyses, enhancing diagnostic precision.
- Molecular Testing Services: This service focuses on the analysis of DNA and/or RNA, along with the structure and function of genes at the molecular level, which is essential for the diagnosis of genetic disorders, infectious diseases, and cancers.
- Morphologic Analysis: Conducting an examination of cells under a microscope allows pathologists to diagnose various conditions accurately based on the appearance and structure of cells.
- Pharmaceutical Services: Supporting pharmaceutical clients’ oncology programs, these services range from the discovery phase through to commercialization, thus facilitating the development of new cancer treatments.
